Biogen price target lowered to $245 from $281 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the ...
Biogen's 2025 forecasts hit by declining sales for MS drugs, strong dollar
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...
BioPharma Dive17h
Biogen inks royalty deal to gain funding for lupus drug R&D
The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition
Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...
Drugmaker Biogen forecasts 2025 profit below expectations
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...
Mint12h
Biogen Pharmachem Industries share price
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Bloomberg L.P.23h
Biogen Pharmachem Industries Ltd
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...